Building a microphysiological skin model from induced pluripotent stem cells

Zongyou Guo, Claire A. Higgins, Brian M. Gillette, Munenari Itoh, Noriko Umegaki, Karl Gledhill, Samuel K. Sia, Angela M. Christiano

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The discovery of induced pluripotent stem cells (iPSCs) in 2006 was a major breakthrough for regenerative medicine. The establishment of patient-specific iPSCs has created the opportunity to model diseases in culture systems, with the potential to rapidly advance the drug discovery field. Current methods of drug discovery are inefficient, with a high proportion of drug candidates failing during clinical trials due to low efficacy and/or high toxicity. Many drugs fail toxicity testing during clinical trials, since the cells on which they have been tested do not adequately model three-dimensional tissues or their interaction with other organs in the body. There is a need to develop microphysiological systems that reliably represent both an intact tissue and also the interaction of a particular tissue with other systems throughout the body. As the port of entry for many drugs is via topical delivery, the skin is the first line of exposure, and also one of the first organs to demonstrate a reaction after systemic drug delivery. In this review, we discuss our strategy to develop a microphysiological system using iPSCs that recapitulates human skin for analyzing the interactions of drugs with the skin.

Original languageEnglish
Article numberS2
JournalStem Cell Research and Therapy
Volume4
Issue numberSUPPL.1
DOIs
Publication statusPublished - 2013 Dec 20
Externally publishedYes

Fingerprint

Induced Pluripotent Stem Cells
Stem cells
Skin
Drug Discovery
Tissue
Clinical Trials
Pharmaceutical Preparations
Toxicity
Regenerative Medicine
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Drug delivery
Testing

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Molecular Medicine
  • Cell Biology
  • Medicine (miscellaneous)

Cite this

Guo, Z., Higgins, C. A., Gillette, B. M., Itoh, M., Umegaki, N., Gledhill, K., ... Christiano, A. M. (2013). Building a microphysiological skin model from induced pluripotent stem cells. Stem Cell Research and Therapy, 4(SUPPL.1), [S2]. https://doi.org/10.1186/scrt363

Building a microphysiological skin model from induced pluripotent stem cells. / Guo, Zongyou; Higgins, Claire A.; Gillette, Brian M.; Itoh, Munenari; Umegaki, Noriko; Gledhill, Karl; Sia, Samuel K.; Christiano, Angela M.

In: Stem Cell Research and Therapy, Vol. 4, No. SUPPL.1, S2, 20.12.2013.

Research output: Contribution to journalArticle

Guo, Z, Higgins, CA, Gillette, BM, Itoh, M, Umegaki, N, Gledhill, K, Sia, SK & Christiano, AM 2013, 'Building a microphysiological skin model from induced pluripotent stem cells', Stem Cell Research and Therapy, vol. 4, no. SUPPL.1, S2. https://doi.org/10.1186/scrt363
Guo Z, Higgins CA, Gillette BM, Itoh M, Umegaki N, Gledhill K et al. Building a microphysiological skin model from induced pluripotent stem cells. Stem Cell Research and Therapy. 2013 Dec 20;4(SUPPL.1). S2. https://doi.org/10.1186/scrt363
Guo, Zongyou ; Higgins, Claire A. ; Gillette, Brian M. ; Itoh, Munenari ; Umegaki, Noriko ; Gledhill, Karl ; Sia, Samuel K. ; Christiano, Angela M. / Building a microphysiological skin model from induced pluripotent stem cells. In: Stem Cell Research and Therapy. 2013 ; Vol. 4, No. SUPPL.1.
@article{aca851ee01544670bbe656ca89257504,
title = "Building a microphysiological skin model from induced pluripotent stem cells",
abstract = "The discovery of induced pluripotent stem cells (iPSCs) in 2006 was a major breakthrough for regenerative medicine. The establishment of patient-specific iPSCs has created the opportunity to model diseases in culture systems, with the potential to rapidly advance the drug discovery field. Current methods of drug discovery are inefficient, with a high proportion of drug candidates failing during clinical trials due to low efficacy and/or high toxicity. Many drugs fail toxicity testing during clinical trials, since the cells on which they have been tested do not adequately model three-dimensional tissues or their interaction with other organs in the body. There is a need to develop microphysiological systems that reliably represent both an intact tissue and also the interaction of a particular tissue with other systems throughout the body. As the port of entry for many drugs is via topical delivery, the skin is the first line of exposure, and also one of the first organs to demonstrate a reaction after systemic drug delivery. In this review, we discuss our strategy to develop a microphysiological system using iPSCs that recapitulates human skin for analyzing the interactions of drugs with the skin.",
author = "Zongyou Guo and Higgins, {Claire A.} and Gillette, {Brian M.} and Munenari Itoh and Noriko Umegaki and Karl Gledhill and Sia, {Samuel K.} and Christiano, {Angela M.}",
year = "2013",
month = "12",
day = "20",
doi = "10.1186/scrt363",
language = "English",
volume = "4",
journal = "Stem Cell Research and Therapy",
issn = "1757-6512",
publisher = "BioMed Central",
number = "SUPPL.1",

}

TY - JOUR

T1 - Building a microphysiological skin model from induced pluripotent stem cells

AU - Guo, Zongyou

AU - Higgins, Claire A.

AU - Gillette, Brian M.

AU - Itoh, Munenari

AU - Umegaki, Noriko

AU - Gledhill, Karl

AU - Sia, Samuel K.

AU - Christiano, Angela M.

PY - 2013/12/20

Y1 - 2013/12/20

N2 - The discovery of induced pluripotent stem cells (iPSCs) in 2006 was a major breakthrough for regenerative medicine. The establishment of patient-specific iPSCs has created the opportunity to model diseases in culture systems, with the potential to rapidly advance the drug discovery field. Current methods of drug discovery are inefficient, with a high proportion of drug candidates failing during clinical trials due to low efficacy and/or high toxicity. Many drugs fail toxicity testing during clinical trials, since the cells on which they have been tested do not adequately model three-dimensional tissues or their interaction with other organs in the body. There is a need to develop microphysiological systems that reliably represent both an intact tissue and also the interaction of a particular tissue with other systems throughout the body. As the port of entry for many drugs is via topical delivery, the skin is the first line of exposure, and also one of the first organs to demonstrate a reaction after systemic drug delivery. In this review, we discuss our strategy to develop a microphysiological system using iPSCs that recapitulates human skin for analyzing the interactions of drugs with the skin.

AB - The discovery of induced pluripotent stem cells (iPSCs) in 2006 was a major breakthrough for regenerative medicine. The establishment of patient-specific iPSCs has created the opportunity to model diseases in culture systems, with the potential to rapidly advance the drug discovery field. Current methods of drug discovery are inefficient, with a high proportion of drug candidates failing during clinical trials due to low efficacy and/or high toxicity. Many drugs fail toxicity testing during clinical trials, since the cells on which they have been tested do not adequately model three-dimensional tissues or their interaction with other organs in the body. There is a need to develop microphysiological systems that reliably represent both an intact tissue and also the interaction of a particular tissue with other systems throughout the body. As the port of entry for many drugs is via topical delivery, the skin is the first line of exposure, and also one of the first organs to demonstrate a reaction after systemic drug delivery. In this review, we discuss our strategy to develop a microphysiological system using iPSCs that recapitulates human skin for analyzing the interactions of drugs with the skin.

UR - http://www.scopus.com/inward/record.url?scp=84891368960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891368960&partnerID=8YFLogxK

U2 - 10.1186/scrt363

DO - 10.1186/scrt363

M3 - Article

C2 - 24564920

AN - SCOPUS:84891368960

VL - 4

JO - Stem Cell Research and Therapy

JF - Stem Cell Research and Therapy

SN - 1757-6512

IS - SUPPL.1

M1 - S2

ER -